跳至主要内容
临床试验/NCT06186856
NCT06186856招募中不适用

Epidemiological Data on Mast Cell Pathologies in France

Imagine Institute36 个研究点 分布在 1 个国家目标入组 13,000 人开始时间: 2024年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
13,000
试验地点
36
主要终点
Epidemiology of mast cell disorders in France assessed by statistics on the prevalence on the various types of mast cell disorders

研究概览

简要总结

Mast cell disorders constitute a heterogeneous group of diseases, including :

  • mastocytosis, i.e. cutaneous, indolent and severe forms of the disease, such as aggressive mastocytosis and mast cell leukemia) ;
  • mast cell-associated diseases such as mast cell activation syndrome (idiopathic, secondary or clonal), affecting both children and adults.

No epidemiological data are currently available in France.

In France, medical care of mast cell disorders is mainly provided by a rare disease network (CEREMAST), whose CRMR is located at the Necker Enfants Malades hospital in Paris. A total of 20 centers are located throughout France.

Our aim is to use this network to study patients suffering from these diseases. The overall aim of the study is to improve the understanding, diagnosis, prognosis, recognition and management of patients with mastocytosis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

性别
All
接受健康志愿者

入选标准

  • Children from birth and adults of any age
  • With one of the following mast cell diseases:
  • Mastocytoses (cutaneous, systemic and sarcomas) Defined according to the WHO 2016 classification
  • Mast cell activation syndromes (idiopathic, secondary and clonal)
  • Other mast cell activation disorders (MCAD-NOS), Defined according to the Vienna classification
  • Pre-mastocytosis or MMC (1 to 2 criteria according to WHO 2016 classification).
  • Managed in France in a rare disease reference, constitutive or competence center (CEREMAST) with DGOS labelization.

排除标准

  • 1. Opposition of the patient or his/her parents to participation in the study.

研究组 & 干预措施

Patients

结局指标

主要结局

Epidemiology of mast cell disorders in France assessed by statistics on the prevalence on the various types of mast cell disorders

时间窗: Data 2010 - 2038

Epidemiology of mast cell disorders in France assessed by statistics on the incidence on the various types of mast cell disorders

时间窗: Data 2010 - 2038

次要结局

  • Patient follow-up assessed by overall survival(Data 2010 - 2038)
  • Types of treatment used on mastocytosis and any associated hemopathy(Data 2010 - 2038)
  • Characteristics of mast cell disease assessed by diagnostic criteria(Data 2010 - 2038)
  • Evolution of mast cell disease assessed by progression of skin lesions(Data 2010 - 2038)
  • Patient characteristics(Data 2010 - 2038)
  • Characteristics of mast cell disease assessed by symptoms of disease(Data 2010 - 2038)
  • Evolution of mast cell disease assessed by progression to aggressive form(Data 2010 - 2038)
  • Evolution of mast cell disease assessed by appearance of new symptoms(Data 2010 - 2038)
  • Characteristics of mast cell disease assessed by type of disease(Data 2010 - 2038)
  • Evolution of mast cell disease assessed by associated hemopathy(Data 2010 - 2038)
  • Patient follow-up assessed by occurrence of other medical events in the patient(Data 2010 - 2038)
  • Tolerance of treatment used on mastocytosis and any associated hemopathy(Data 2010 - 2038)
  • Efficacy of treatment used on mastocytosis and any associated hemopathy(Data 2010 - 2038)

研究者

发起方
Imagine Institute
申办方类型
Other
责任方
Sponsor

研究点 (36)

Loading locations...

相似试验